Lumaegis has been named a 2024 RadLaunch Challenge winner and secured $200,000 in funding as it prepares for FDA testing of its RadBox sterilization device.
Lumaegis Inc has been named a 2024 RadLaunch Challenge Winner by the International Ultraviolet Association. The honor recognizes the company’s work on solid-state lighting-based sterilization technologies, including its lead product, the RadBox.
$200,000 Pre-Seed Round Completed
The Austin-based company also announced the close of a $200,000 pre-seed funding round. The investment was led by a global strategic partner and will be used to build production units and conduct FDA, UL/CE, and longevity testing. Lumaegis is a member of the University of Texas’ Austin Technology Incubator.
RadBox Cleared for De Novo FDA Classification
The RadBox has received FDA De Novo classification, indicating that it qualifies as a breakthrough device with no existing approved predicate. The device combines germicidal and thermal radiation via LEDs and is positioned as an energy-efficient alternative to traditional sterilization equipment.
Lumaegis expects to begin FDA-required testing later this year. The company has a key patent granted and additional patent applications pending.
2026 Launch Target
“We anticipate our first sales in 2026,” said CEO John S. Morreale. “Production will begin that year, and we already have customers lined up. Many dental professionals who collaborated with us during the RadBox design phase will be among our first users, providing essential clinical feedback. Additionally, we’ve secured our first major customer — a global industry partner and investor in the disinfection and sterilization space — representing over 2,000 units in initial sales.”
Photo:
